Table 2.

Serum Lysyl Oxidase levels in ovarian cancer patients stratified based on clinical stages and its comparison with Control subjects.

Serum Lysyl Oxidase (ng/mL)	Control Subjects (n = 86)	Cases (Ovarian Cancer) (n = 83) FIGO Stage
		I, II	III, IV
	1.61 ± 0.47	3.28 ± 0.66	* 5.01 ± 1.05
		TNM grade
		1,2	3
	1.61 ± 0.47	3.42 ± 0.78	* 4.89 ± 1.16
FIGO: International Federation of Gynecology and Obstetrics staging TNM: Tumor, Lymph Node and Metastasis grade

* indicates p < 0.05, is considered statistically significant as compared to FIGO Stage I, II and TNM grade 1,2.